Stomach Cancer Clinical Trial
Official title:
Efficacy and Safety of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in Patients With HER2-positive Resectable Gastric or Gastr-oesophageal Junction Carcinoma (GC/EGJ) -- a Prospective, Single-arm, Phase II Study
Perioperative chemotherapy improves overall survival (OS) and disease-free survival (DFS) compared with surgery alone in patients with resectable gastric adenocarcinoma (GA) or gastro-oesophageal junction adenocarcinoma (GEJA). The addition of tislelizumab and trastuzumab to chemotherapy improves outcomes in patients with HER2-positive advanced gastric cancer (GC), and the investigators aimed to explore its role in the perioperative setting.
This study will evaluate the pathologic complete response rate of a perioperative chemotherapy combined with tislelizumab and Trastuzumab in patients with resectable gastric cancer. Prior to surgery to resect the tumor, tislelizumab (intravenously, 200 mg on day 1 of every cycle) and trastuzumab (intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle) will be administered for four cycles and the perioperative chemotherapy contains docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle) and S1 (orally, 400mg/m2 BID on day 1~14 of every cycle) and Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle) will be administered for three cycles prior to surgery.If complete resection, R0 or microscopic residual tumor R1 is achieved, patients will continue with three cycles of SOX and tislelizumab and trastuzumab and then for completion of 12 months treatment with tislelizumab and trastuzumab alone. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
| Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT02604979 -
The Influences of Long Periods of Pneumoperitoneum and Head up Position on the Variation of Heart-rate Corrected QT Interval During Robotic-assisted Laparoscopic Gastrectomy - Observational Study
|
N/A | |
| Active, not recruiting |
NCT00394433 -
Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
|
Phase 2 | |
| Completed |
NCT00201747 -
Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer
|
Phase 2 | |
| Completed |
NCT00215514 -
Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 0 | |
| Recruiting |
NCT04486651 -
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
|
Phase 3 | |
| Recruiting |
NCT05415475 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT04526470 -
Alpelisib and Paclitaxel in PIK3CA-altered Gastric Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01257711 -
A Study Comparing Billroth II With Roux-en-Y Reconstruction for Gastric Cancer
|
N/A | |
| Recruiting |
NCT04907643 -
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
|
N/A | |
| Withdrawn |
NCT03704077 -
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT04484636 -
PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
|
N/A | |
| Recruiting |
NCT05489250 -
The PLATON Network
|
||
| Completed |
NCT02547064 -
Effect of Modified Stylet Angulation on the Intubation With GlideScope®
|
N/A | |
| Withdrawn |
NCT00800969 -
Prospective Evaluation of the Preoperative Lymph Node Staging in Patients With Cancer of the Esophagogastric Junction and Stomach
|
Phase 2 | |
| Completed |
NCT00296322 -
Trial of Adjuvant Chemotherapy for Gastric Cancer
|
Phase 3 | |
| Recruiting |
NCT04215861 -
Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy
|
||
| Recruiting |
NCT06199895 -
Clinical Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Patients With Taxans-resistant Pancreatic Adenocarcinoma, Cholangiocarcinoma, Lung Cancer, Gastric Cancer, Esophageal Carcinoma, or Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT01038154 -
Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
|
Phase 4 |